VELCADE Administered by intravenous infusion — Competitive Intelligence Brief

VELCADE Administered by intravenous infusion (VELCADE Administered by intravenous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

phase 3 Proteasome inhibitor 26S proteasome Oncology Small molecule

Target snapshot

VELCADE Administered by intravenous infusion (VELCADE Administered by intravenous infusion) — Millennium Pharmaceuticals, Inc.. VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VELCADE Administered by intravenous infusion TARGET	VELCADE Administered by intravenous infusion	Millennium Pharmaceuticals, Inc.	phase 3	Proteasome inhibitor	26S proteasome
Velcade	bortezomib	Shilpa	marketed	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
Velcade	Velcade	University of Arkansas	marketed		26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Bortezomib (B)	Bortezomib (B)	National Cancer Institute (NCI)	marketed	Proteasome inhibitor	26S proteasome
CDD Plus Bortezomib	CDD Plus Bortezomib	Beijing Chao Yang Hospital	phase 3	Proteasome inhibitor combined with chemotherapy	26S proteasome

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-11-03 — Velcade · 8962572 · Formulation · US
• 2042-09-23 — Velcade · 11752164 · Method of Use · US
• 2042-09-23 — Velcade · 11679119 · Method of Use · US
• 2042-09-23 — Velcade · 12005069 · Formulation · US

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class